These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

877 related items for PubMed ID: 21297257

  • 21. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition.
    Stumm C, Hiebel C, Hanstein R, Purrio M, Nagel H, Conrad A, Lutz B, Behl C, Clement AB.
    Neurobiol Aging; 2013 Nov; 34(11):2574-84. PubMed ID: 23838176
    [Abstract] [Full Text] [Related]

  • 22. Repeated novel cage exposure-induced improvement of early Alzheimer's-like cognitive and amyloid changes in TASTPM mice is unrelated to changes in brain endocannabinoids levels.
    Pardon MC, Sarmad S, Rattray I, Bates TE, Scullion GA, Marsden CA, Barrett DA, Lowe J, Kendall DA.
    Neurobiol Aging; 2009 Jul; 30(7):1099-113. PubMed ID: 18023506
    [Abstract] [Full Text] [Related]

  • 23. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms.
    Costa DA, Cracchiolo JR, Bachstetter AD, Hughes TF, Bales KR, Paul SM, Mervis RF, Arendash GW, Potter H.
    Neurobiol Aging; 2007 Jun; 28(6):831-44. PubMed ID: 16730391
    [Abstract] [Full Text] [Related]

  • 24. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 1. Circadian changes.
    Sterniczuk R, Dyck RH, Laferla FM, Antle MC.
    Brain Res; 2010 Aug 12; 1348():139-48. PubMed ID: 20471965
    [Abstract] [Full Text] [Related]

  • 25. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.
    Do TM, Alata W, Dodacki A, Traversy MT, Chacun H, Pradier L, Scherrmann JM, Farinotti R, Calon F, Bourasset F.
    Neuropharmacology; 2014 Jun 12; 81():311-7. PubMed ID: 24631967
    [Abstract] [Full Text] [Related]

  • 26. Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons.
    Chiba T, Yamada M, Sasabe J, Terashita K, Shimoda M, Matsuoka M, Aiso S.
    Mol Psychiatry; 2009 Feb 12; 14(2):206-22. PubMed ID: 18813209
    [Abstract] [Full Text] [Related]

  • 27. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice.
    Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X, Echeverria V, Potter H.
    J Alzheimers Dis; 2009 Feb 12; 17(3):661-80. PubMed ID: 19581722
    [Abstract] [Full Text] [Related]

  • 28. A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease.
    Bonardi C, de Pulford F, Jennings D, Pardon MC.
    Behav Brain Res; 2011 Sep 12; 222(1):89-97. PubMed ID: 21440575
    [Abstract] [Full Text] [Related]

  • 29. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
    Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O.
    Ann Neurol; 2004 Jun 12; 55(6):801-14. PubMed ID: 15174014
    [Abstract] [Full Text] [Related]

  • 30. Vitamin C restores behavioral deficits and amyloid-β oligomerization without affecting plaque formation in a mouse model of Alzheimer's disease.
    Murakami K, Murata N, Ozawa Y, Kinoshita N, Irie K, Shirasawa T, Shimizu T.
    J Alzheimers Dis; 2011 Jun 12; 26(1):7-18. PubMed ID: 21558647
    [Abstract] [Full Text] [Related]

  • 31. 4-O-methylhonokiol prevents memory impairment in the Tg2576 transgenic mice model of Alzheimer's disease via regulation of β-secretase activity.
    Lee YJ, Choi DY, Lee YK, Lee YM, Han SB, Kim YH, Kim KH, Nam SY, Lee BJ, Kang JK, Yun YW, Oh KW, Hong JT.
    J Alzheimers Dis; 2012 Jun 12; 29(3):677-90. PubMed ID: 22330831
    [Abstract] [Full Text] [Related]

  • 32. Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.
    Morin JP, Cerón-Solano G, Velázquez-Campos G, Pacheco-López G, Bermúdez-Rattoni F, Díaz-Cintra S.
    J Alzheimers Dis; 2016 Jun 12; 51(1):69-79. PubMed ID: 26836189
    [Abstract] [Full Text] [Related]

  • 33. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment.
    Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC.
    J Alzheimers Dis; 2010 Jun 12; 20(1):113-26. PubMed ID: 20164597
    [Abstract] [Full Text] [Related]

  • 34. Impaired neuronal insulin signaling precedes Aβ42 accumulation in female AβPPsw/PS1ΔE9 mice.
    Chua LM, Lim ML, Chong PR, Hu ZP, Cheung NS, Wong BS.
    J Alzheimers Dis; 2012 Jun 12; 29(4):783-91. PubMed ID: 22337827
    [Abstract] [Full Text] [Related]

  • 35. Oxidative Stress Is a Central Target for Physical Exercise Neuroprotection Against Pathological Brain Aging.
    García-Mesa Y, Colie S, Corpas R, Cristòfol R, Comellas F, Nebreda AR, Giménez-Llort L, Sanfeliu C.
    J Gerontol A Biol Sci Med Sci; 2016 Jan 12; 71(1):40-9. PubMed ID: 25720862
    [Abstract] [Full Text] [Related]

  • 36. The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice.
    Sabogal-Guáqueta AM, Muñoz-Manco JI, Ramírez-Pineda JR, Lamprea-Rodriguez M, Osorio E, Cardona-Gómez GP.
    Neuropharmacology; 2015 Jun 12; 93():134-45. PubMed ID: 25666032
    [Abstract] [Full Text] [Related]

  • 37. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K, Prelli F, Mehta P, MacMurray C, Goñi F, Wisniewski T.
    Alzheimers Res Ther; 2018 Jun 18; 10(1):54. PubMed ID: 29914551
    [Abstract] [Full Text] [Related]

  • 38. Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice.
    Cuadrado-Tejedor M, Ricobaraza A, Frechilla D, Franco R, Pérez-Mediavilla A, Garcia-Osta A.
    J Alzheimers Dis; 2012 Jun 18; 28(3):567-78. PubMed ID: 22045482
    [Abstract] [Full Text] [Related]

  • 39. Characterization of cognition alteration across the course of the disease in APP751SL mice with parallel estimation of cerebral Abeta deposition.
    Blanchard J, Decorte L, Noguès X, Micheau J.
    Behav Brain Res; 2009 Jul 19; 201(1):147-57. PubMed ID: 19428628
    [Abstract] [Full Text] [Related]

  • 40. Transgenic autoinhibition of p21-activated kinase exacerbates synaptic impairments and fronto-dependent behavioral deficits in an animal model of Alzheimer's disease.
    Bories C, Arsenault D, Lemire M, Tremblay C, De Koninck Y, Calon F.
    Aging (Albany NY); 2017 May 16; 9(5):1386-1403. PubMed ID: 28522792
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.